IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, April 27, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. When this information was released, the Company’s stock price decreased materially, which harmed investors according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/